Formulation and in vitro assessment of Rutin-loaded Chitosan/Guar Gum Nanoparticles for Targeting Ovarian Cancer cells
This study demonstrates that rutin-loaded chitosan/guar gum nanoparticles, developed via ionic gelation, significantly enhance the solubility, stability, and targeted delivery of rutin to ovarian cancer cells, resulting in superior cytotoxicity and apoptosis induction compared to free rutin.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer remains one of the most formidable challenges in modern medicine, a disease where cells lose their ability to follow the body's rules and multiply uncontrollably. Among the many forms of this disease, ovarian cancer is particularly dangerous because it often grows silently, hiding in the early stages until it has spread widely. While doctors have various tools to fight it, including surgery and chemotherapy, these treatments often come with severe side effects because they cannot easily distinguish between the rogue cancer cells and the healthy ones. In response, scientists are increasingly turning to nature for solutions, looking at plant-based compounds that have shown promise in fighting disease but struggle to work effectively inside the human body. One such compound is rutin, a substance found in many fruits and vegetables like apples and onions. Rutin has strong properties that can stop cancer cells from growing, but it faces a significant hurdle: it does not dissolve well in water and breaks down too quickly to reach its target in high enough doses. To solve this, researchers are exploring a method called nanotechnology, which involves building microscopic carriers to protect drugs and deliver them precisely where they are needed.
In a recent study, a team of scientists set out to create a new delivery system for rutin specifically designed to target ovarian cancer cells. They focused on a type of cancer cell known as SKOV-3, which is commonly used in research to understand how the disease behaves. The researchers built tiny spheres, or nanoparticles, using two natural materials: chitosan, which comes from the shells of crustaceans, and guar gum, a thickening agent derived from a plant seed. These materials were chosen because they are safe for the body and can be engineered to hold onto drugs. The team mixed rutin with chitosan to form the core of the particle and then coated it with guar gum to make it more stable. The goal was to create a vehicle that could carry the rutin safely through the body, protect it from breaking down, and release it only when it reached the cancer cells.
The results of their work showed that the new nanoparticles were highly effective at holding the drug. The team found that the particles were incredibly small, measuring about 43 nanometers in diameter, which is roughly the size of a large virus. They also discovered that the particles carried a strong positive electrical charge, a feature that helps them stick to and enter cancer cells, which typically have a negative charge on their surface. When the researchers tested how well the nanoparticles held the rutin, they found that nearly 87 percent of the drug was successfully trapped inside the carrier. This is a crucial finding because it means very little of the valuable medicine is wasted during the delivery process.
Once the particles were built, the scientists tested how they would behave in different environments. They simulated the conditions found in the human body, including the slightly acidic environment often found inside tumors. The particles proved to be very stable, but they also showed a smart behavior: they released the rutin more quickly when the environment was slightly acidic, mimicking the conditions inside a tumor. This suggests that the nanoparticles could act like a smart delivery truck, holding onto the drug while traveling through the bloodstream and then opening up to release their cargo specifically where the cancer cells are located.
The most critical part of the study involved testing whether these nanoparticles could actually kill the cancer cells. The researchers exposed the ovarian cancer cells to the rutin-loaded nanoparticles and compared the results to cells treated with rutin alone. The cells treated with the nanoparticles died much faster and in greater numbers. After 24 hours, the nanoparticles reduced the number of living cancer cells to about 26 percent, whereas the rutin alone only reduced it to about 40 percent. Even more importantly, the nanoparticles did not harm healthy cells. When the team tested the same particles on normal fibroblast cells, which are healthy cells found in connective tissue, the cells remained almost completely alive, with over 93 percent surviving. This indicates that the new delivery system is precise, attacking the cancer while leaving the healthy tissue unharmed.
To understand how the nanoparticles killed the cancer cells, the researchers looked inside the cells to see what was happening. They found that the nanoparticles caused the cancer cells to undergo a process called apoptosis, which is a form of programmed cell death. The cells showed clear signs of dying, such as their nuclei shrinking and their membranes becoming distorted. The treatment also caused a surge in harmful molecules called reactive oxygen species inside the cancer cells, which damaged the cells from the inside out. Additionally, the nanoparticles disrupted the energy centers of the cells, known as mitochondria, causing them to lose their ability to function. These internal failures triggered the cell's self-destruct mechanism, leading to the death of the cancer cell.
The study also used computer simulations to predict which specific targets the rutin might be hitting inside the cells. The analysis pointed to a protein called ESR1, which is involved in cell growth and is often linked to ovarian cancer. The computer models suggested that rutin binds very tightly to this protein, effectively blocking its ability to help the cancer grow. While these computer models provide a strong hint at how the drug works, the researchers noted that the physical experiments confirmed the overall success of the delivery system. The nanoparticles successfully delivered the drug, increased its effectiveness, and reduced its toxicity to healthy cells.
This research represents a significant step forward in how we might treat ovarian cancer in the future. By wrapping a natural plant compound in a protective, natural shell, the scientists created a tool that is more potent and safer than the drug on its own. The study confirms that it is possible to engineer a system that delivers a difficult-to-use medicine directly to a tumor, sparing the rest of the body from harm. While more testing is needed to see how this works in living animals and eventually in people, the findings offer a hopeful glimpse into a future where cancer treatments are not only more effective but also kinder to the patients who need them. The work demonstrates that by understanding the unique properties of both the drug and the cancer, scientists can build bridges that carry life-saving treatments right to the door of the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.